Hypertension

Sustained elevation of arterial blood pressure above clinically defined thresholds, and one of the largest modifiable contributors to cardiovascular and all-cause mortality worldwide. In the aging context, hypertension is both an end-organ manifestation of vascular aging and an accelerator of downstream pathologies including atherosclerosis, arterial stiffening, heart-failure, chronic kidney disease, and vascular neurodegeneration.

Systolic blood pressure (SBP) rises continuously with age in most populations; diastolic pressure (DBP) plateaus or falls after age 55–60 in many individuals as aortic compliance decreases, producing isolated systolic hypertension — the dominant phenotype in older adults and the pattern most strongly linked to cardiovascular and cerebrovascular risk ¹.

Definition and thresholds

The dominant guideline frameworks define hypertension differently:

Guideline	Normal	Elevated	Stage 1 HTN	Stage 2 HTN
ACC/AHA 2017 ²	<120/<80	120–129/<80	130–139 / 80–89	≥140/≥90
ESC/ESH 2018	<120/<80	120–129/80–84	Grade 1: 140–159/90–99	Grade 2/3: ≥160/≥100
JNC-7 (older)	<120/<80	120–139/80–89 (prehypertension)	≥140/≥90	—

The 2017 ACC/AHA reclassification of the 130–139/80–89 mm Hg range as Stage 1 hypertension (replacing the “prehypertension” label) substantially increased the estimated prevalence of hypertension in US adults and was accompanied by stronger emphasis on lifestyle intervention in this range. No consensus exists across international guidelines — clinicians should note which threshold applies when interpreting prevalence figures.

Isolated systolic hypertension (ISH): SBP ≥140 mm Hg with DBP <90 mm Hg. Most common pattern in adults >60; driven primarily by aortic stiffening reducing diastolic filling of the windkessel. Associated with elevated pulse pressure (PP = SBP − DBP), itself an independent cardiovascular risk marker.

The continuous SBP-risk relationship

The defining epidemiological finding for hypertension in aging is that cardiovascular risk increases log-linearly with SBP throughout the entire usual blood pressure range, with no threshold down to at least 115/75 mm Hg ¹. The Prospective Studies Collaboration pooled individual-participant data from 1 million adults across 61 prospective cohort studies; each 20 mm Hg difference in usual SBP (or ~10 mm Hg diastolic) was associated with a greater than 2-fold difference in stroke mortality and approximately 2-fold differences in ischemic heart disease mortality at ages 40–69 years ¹.

Key implications:

There is no “safe” blood pressure level in this framework — risk reduction from lowering SBP is continuous.
The absolute risk at any SBP level is strongly age-dependent: the same proportional hazard translates to far more excess events per year in a 70-year-old than a 40-year-old.
Proportional risk associations diminish somewhat at ages 80–89 (roughly halved), though absolute annual excess risk remains substantial in older individuals ¹.

Prevalence and aging trajectory

In US adults, hypertension prevalence increases steeply with age. NHANES-based estimates (2017–2018, ACC/AHA 2017 thresholds):

Adults 18–39: ~22–25%
Adults 40–59: ~55%
Adults 60–79: ~74%
Adults ≥80: ~80%+

Overall controlled BP (SBP <140/DBP <90, JNC-7 threshold) among US adults with hypertension peaked at 53.8% in 2013–2014 and declined to 43.7% by 2017–2018, reflecting a widening treatment gap in the latter NHANES cycles ³. Blood pressure control disparities are prominent by race/ethnicity (lower control in non-Hispanic Black adults) and by sex.

High SBP is the world’s leading attributable risk factor for disability-adjusted life years. The Global Burden of Disease 2023 analysis identified high SBP as responsible for 8.4% of total DALYs globally ⁴.

Pathophysiology in the aging context

Hypertension in older adults is predominantly a structural vascular disease rather than a purely hemodynamic one. Multiple age-related processes converge:

Arterial stiffening

The primary driver of isolated systolic hypertension in aging. Central elastic arteries (aorta, common carotids) undergo progressive stiffening through: accumulation of AGEs (advanced glycation end-products) cross-linking collagen and elastin; elastic fiber fragmentation; smooth muscle hypertrophy; and calcification. This reduces the Windkessel buffering function, increasing pulse wave velocity (PWV) and returning reflected pulse waves to the heart earlier in systole — amplifying SBP and reducing DBP ⁵.

Critically, the relationship is bidirectional: elevated SBP accelerates arterial stiffening, which further raises SBP — creating a reinforcing cycle with arterial-stiffening.

Endothelial dysfunction

Age-associated endothelial dysfunction reduces nitric oxide (NO) bioavailability through: increased oxidative stress (superoxide quenching NO); reduced eNOS expression and activity; reduced sensitivity to shear-stress-mediated NO release. Reduced NO impairs vasodilation, increases peripheral vascular resistance, and promotes vascular smooth muscle hypertrophy. Cellular senescence in endothelial cells and VSMCs contributes through SASP (senescence-associated secretory phenotype) mediators driving local inflammation ⁶ — connecting cellular-senescence to vascular stiffening.

Renin-angiotensin-sympathetic axis

Aging is associated with enhanced sympathetic nervous system activity and parasympathetic decline, increasing peripheral resistance. The renin-angiotensin system (RAS) shifts toward a pro-hypertensive angiotensin-II dominant state relative to the cardioprotective angiotensin-(1–7) counter-regulatory axis ⁷. Angiotensin II drives vasoconstriction, aldosterone-mediated (mineralocorticoid receptor) sodium retention, and vascular inflammation/fibrosis. Central nervous system changes (hypothalamic overactivation, microglial neuroinflammation in circumventricular organs) also contribute to sympathetic overdrive ⁸.

Mitochondrial dysfunction and oxidative stress

Vascular mitochondria become dysfunctional with age — reduced oxidative phosphorylation efficiency, increased reactive oxygen species (ROS) leak, and impaired quality control. Excess mitochondrial ROS drives both endothelial dysfunction (eNOS uncoupling) and vascular smooth muscle stiffening ⁹. Connects mitochondrial-dysfunction to hypertension pathogenesis.

Chronic inflammation

Elevated circulating pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and SASP from senescent vascular cells promote endothelial dysfunction, promote monocyte infiltration, and activate RAAS. Inflammaging (see chronic-inflammation) is thus both upstream and downstream of elevated blood pressure, through immune infiltration in perivascular adventitia, macrophage-mediated ROS production, and autoimmune mechanisms involving effector T-cell accumulation in kidneys and vasculature ⁶.

Sodium handling and renal aging

Age-related decline in renal mass and glomerular filtration rate reduces the kidney’s capacity to excrete sodium loads, shifting the pressure-natriuresis relationship. Salt sensitivity increases with age — a sodium load that would not elevate BP in a young kidney may sustain hypertension in an aging one. This underlies the larger treatment response to sodium restriction and thiazide/thiazide-like diuretics in older adults.

Downstream pathologies

Hypertension is the principal modifiable driver of all major end-organ damage categories in older adults:

Cardiovascular

atherosclerosis — elevated shear stress and endothelial injury accelerate atheromatous plaque formation; hypertension is the leading attributable risk factor for MI and stroke
arterial-stiffening — bidirectional: stiffening causes ISH; ISH worsens stiffening
heart-failure — LV hypertrophy (pressure overload) → diastolic dysfunction → HFpEF (heart failure with preserved ejection fraction); long-term HTN also causes HFrEF via LV remodeling
Atrial fibrillation — LV hypertrophy and fibrosis are major AF substrates

Renal

chronic-kidney-disease (stub) — hypertension is both a cause and consequence of CKD; sustained elevated intraglomerular pressure drives glomerulosclerosis; loss of GFR worsens sodium retention and BP, closing a bidirectional loop

Cerebrovascular and cognitive

Stroke — hypertension is the single largest modifiable stroke risk factor (both hemorrhagic and ischemic) ¹⁰
Vascular neurodegeneration — chronic hypoperfusion and microvascular disease drive white matter lesions and vascular dementia; SPRINT-MIND found intensive SBP control (<120 mm Hg) reduced mild cognitive impairment vs standard control (<140 mm Hg), though probable dementia reduction did not reach statistical significance at the trial’s follow-up ¹¹
Accelerated cognitive decline — long-term BP variability (independently of mean BP) is associated with accelerated global cognitive decline in older adults ¹²

Clinical evidence for treatment

SPRINT (2015) — landmark intensive BP-lowering trial

Randomized 9,361 adults with SBP ≥130 mm Hg and elevated CV risk (excluding diabetes) to intensive treatment (SBP target <120 mm Hg) vs standard (SBP target <140 mm Hg). The trial stopped early for benefit ¹³:

Primary composite MACE endpoint: HR 0.75 (intensive vs standard), 1.65% vs 2.19%/year
All-cause mortality: HR 0.73
Higher rates of acute kidney injury, hypotension, syncope, and electrolyte abnormalities in intensive arm (no significant increase in injurious falls)

SPRINT provides the most rigorous human evidence that treating below the traditional 140 mm Hg threshold reduces cardiovascular events in a non-diabetic high-risk older population.

STEP trial (2021, Asian elderly 60–80)

An RCT of 8,511 Chinese adults age 60–80 confirmed intensive BP targets (SBP 110–<130 mm Hg) reduced MACE vs standard (SBP 130–<150 mm Hg) in elderly Asian patients, extending the SPRINT evidence base to an older cohort in an Asian population with high stroke burden ¹⁴.

Effect size summary

Intervention	SBP reduction	Evidence source
Lifestyle (Na restriction + DASH + exercise)	5–15 mm Hg	Multiple RCTs
Each antihypertensive drug class (mono)	8–12 mm Hg	Large meta-analyses
Mediterranean diet (older adults 65–79)	−5.5 mm Hg SBP (males −9.2, females −3.1 ns) ¹⁵	RCT n=1,128 (BP analysis)
Sodium restriction (intervention page)	See sodium-restriction	—

For a given starting SBP, each 10 mm Hg sustained reduction is estimated to reduce major cardiovascular events by ~20% and stroke by ~27% (based on observational scaling from Lewington 2002, supported by clinical trial data).

Drivers and modifiable risk factors

Major modifiable contributors:

Dietary sodium — dose-response between sodium intake and BP; salt sensitivity increases with age. See sodium-restriction.
Obesity — adipose expansion raises renal sympathetic tone and RAAS activity; adipokine dysregulation impairs endothelial function. See obesity (stub). gap/stub
Alcohol — dose-dependent pressor effect of chronic alcohol consumption; mechanisms include sympathetic activation, cortisol elevation, endothelial dysfunction. See alcohol (stub). gap/stub
Physical inactivity — habitual aerobic exercise reduces resting SBP by ~3–7 mm Hg; mechanisms include improved endothelial function, reduced sympathetic tone, and improved arterial compliance
Sleep disorders — obstructive sleep apnea is a secondary cause of hypertension through intermittent hypoxia and sympathetic activation (see also sleep)
Smoking — acute vasopressor effect; long-term vascular injury
Age — non-modifiable biological driver through the arterial stiffening-senescence-inflammation cascade described above

Hallmark mapping

Hypertension sits at the intersection of multiple hallmarks-of-aging as both a downstream consequence and a reinforcing driver:

Hallmark	Relationship to hypertension
chronic-inflammation	Inflammaging cytokines drive endothelial dysfunction and RAAS; hypertension reciprocally elevates vascular inflammation
cellular-senescence	VSMC and endothelial senescence via SASP → vascular stiffening and dysfunction
altered-intercellular-communication	Dysregulated paracrine NO/angiotensin signaling; impaired endothelium-smooth muscle crosstalk
mitochondrial-dysfunction	Mitochondrial ROS in vessels → eNOS uncoupling and stiffening

Limitations and gaps

Threshold debates — the ACC/AHA 2017 threshold (130/80) vs the older 140/90 threshold remains contested; prevalence figures vary substantially depending on which cutpoint is applied. gap/contradictory-evidence
Treatment benefit in the oldest old (≥80) — evidence for benefit of aggressive treatment in frail adults >80 is limited; the HYVET trial suggested benefit at SBP ≥160 in >80s but the optimal lower target in this group is uncertain. gap/needs-replication
Optimal target in diabetes — diabetics were excluded from SPRINT, and the earlier ACCORD-BP trial found no significant CV-event reduction from intensive (<120) vs standard (<140) SBP control in type-2 diabetes. However, the larger BPROAD trial (2025, n=12,821 Chinese adults with T2D) reported that an intensive SBP target (<120) did reduce major cardiovascular events vs standard (<140): HR 0.79 (95% CI 0.69–0.90; P<0.001) ¹⁶. The current weight of evidence thus favors a benefit of intensive control in diabetes, reconciling the earlier ACCORD null (smaller, 2×2 factorial with glycemia arm) toward the SPRINT-direction result. gap/contradictory-evidence
Vascular dementia endpoint — SPRINT-MIND failed to reach statistical significance for dementia reduction (HR 0.83, not significant), though MCI was significantly reduced; longer follow-up studies needed. gap/needs-replication
Mechanistic link obesity→hypertension — cross-linked to obesity, but no integrated quantitative mediation analysis (how much of the obesity→CVD effect runs through blood pressure) has been assembled yet. gap/no-mechanism

Footnotes

doi:10.1016/S0140-6736(02)11911-8 · Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration · Lancet 2002;360(9349):1903–1913 · PMID 12493255 · meta-analysis · n=1,000,000 in 61 prospective studies; 12.7 million person-years; ~56,000 vascular deaths · each 20 mm Hg lower usual SBP associated with >2-fold lower stroke mortality at ages 40–69; linear down to ≥115/75 with no threshold · model: human (observational) · gap/no-fulltext-access (closed-access) ↩ ↩² ↩³ ↩⁴
doi:10.1161/HYP.0000000000000066 · Whelton PK et al. · Hypertension 2018;71(6):e13–e115 · PMID 29133354 · consensus guideline · 2017 ACC/AHA hypertension guideline; redefined Stage 1 HTN as ≥130/80 mm Hg; n/a (clinical practice guideline) · gap/no-fulltext-access (closed-access) ↩
doi:10.1001/jama.2020.14545 · Muntner P, Hardy ST, Fine LJ et al. · JAMA 2020;324(12):1190–1200 · PMID 32902588 · observational (NHANES serial cross-sections) · n=51,761 total participants (18,262 with hypertension by JNC-7 definition: SBP ≥140 or DBP ≥90 or antihypertensive medication use) across 10 survey cycles 1999–2018 · BP control (defined as SBP <140 and DBP <90) peaked 53.8% (2013–14) then declined to 43.7% (2017–18) among all US adults with hypertension (not restricted to treated subgroup) · model: US adult population ↩
doi:10.1016/S0140-6736(25)01637-X · GBD 2023 Disease and Injury and Risk Factor Collaborators · Lancet 2025 · PMID 41092926 · systematic analysis 204 countries; high SBP 8.4% of total global DALYs; leading single modifiable risk factor for cardiovascular mortality worldwide ↩
doi:10.1161/CIRCRESAHA.121.318061 · Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF · Circ Res 2021;128(7):1034–1056 · PMID 33793325 · review · arterial stiffness → structural BP feedback loops; PWV and augmentation index as risk markers in hypertension; antihypertensive agents reduce stiffness beyond passive BP lowering; model: human + animal data ↩
doi:10.1007/s00018-021-03979-4 · Raucci A, Macrì F, Castiglione S, Badi I, Vinci MC, Zuccolo E · Cell Mol Life Sci 2022;79(1):23 · PMID 34698884 · review · miR-34a-mediated SIRT1 suppression induces senescence and SASP in vascular smooth muscle cells and endothelial cells; links cellular-senescence → hypertension-relevant endothelial dysfunction · model: in-vitro + murine + human tissue ↩ ↩²
doi:10.1016/j.peptides.2021.170733 · Miller AJ, Arnold AC · Peptides 2022;149:170733 · PMID 34973286 · review · aging-associated shift toward sympathetic enhancement and Ang-II dominant RAAS state; parasympathetic decline; Ang-(1–7) counter-regulatory axis; model: human + rodent data ↩
doi:10.2147/JIR.S350109 · Wang M, Pan W, Xu Y et al. · J Inflamm Res 2022;15:2917–2930 · PMID 35642214 · review · microglial neuroinflammation in hypertension; prorenin receptor, TLR4, TREM2, P2X7 signaling; hypothalamic autonomic circuits in BP regulation · model: rodent + human tissue ↩
doi:10.1016/j.mad.2020.111267 · Forte M, Stanzione R, Cotugno M et al. · Mech Ageing Dev 2020;189:111267 · PMID 32473170 · review · vascular mitochondrial dysfunction in hypertension-related aging: ROS generation, eNOS uncoupling, impaired oxidative phosphorylation; links mitochondrial-dysfunction → arterial stiffening and endothelial dysfunction · model: rodent + in-vitro + human data ↩
doi:10.1016/S1474-4422(24)00369-7 · GBD 2021 Stroke Risk Factor Collaborators (Feigin VL et al.) · Lancet Neurol 2024;23(10):973–1003 · PMID 39304265 · systematic analysis · n=204 countries 1990–2021; high SBP among leading attributable risk factors for stroke DALYs; 7.3 million stroke deaths in 2021; model: global population epidemiology ↩
doi:10.1001/jama.2018.21442 · Williamson JD, Pajewski NM, Auchus AP et al.; SPRINT MIND Investigators · JAMA 2019;321(6):553–561 · PMID 30688979 · RCT sub-study · n=9,361 (same as SPRINT); median follow-up 5.11 yr; intensive vs standard BP; probable dementia HR 0.83 (95% CI 0.67–1.04, ns); MCI HR 0.81 (95% CI 0.69–0.95, significant); combined MCI/dementia HR 0.85 (95% CI 0.74–0.97, significant); exact p-values not reported in abstract — full text not verified; trial stopped early may have underpowered dementia endpoint · model: human (SPRINT substudy) ↩
doi:10.1161/STROKEAHA.120.033697 · Li C, Ma Y, Hua R et al. · Stroke 2021;52(8):2640–2649 · PMID 34167328 · observational prospective · n=12,298 dementia-free adults (mean age 64.6 yr); 10% increase in SBP variability → 0.026 SD/y accelerated global cognitive decline; nonlinear relationship with inflection; model: human cohort ↩
doi:10.1056/NEJMoa1511939 · SPRINT Research Group (Wright JT Jr, Williamson JD, Whelton PK et al.) · N Engl J Med 2015;373(22):2103–2116 · PMID 26551272 · RCT · n=9,361; randomized; intensive (<120 mm Hg) vs standard (<140 mm Hg) SBP target; median follow-up 3.26 yr (stopped early); HR for primary MACE 0.75 (95% CI 0.64–0.89); all-cause mortality HR 0.73; model: human adults ≥50 yr with SBP ≥130 + elevated CV risk (no diabetes) ↩
doi:10.1038/s41440-022-00875-7 · Zhang WL, Cai J · Hypertension Res 2022;45(6):943–951 · PMID 35277670 · review · evidence synthesis on STEP trial (n=8,511 Chinese adults 60–80 yr); intensive SBP 110–<130 mm Hg vs standard 130–<150 mm Hg; reduced MACE in elderly Asian patients; higher stroke-benefit in Asian populations · model: human RCT (Asian elderly) ↩
doi:10.1161/HYPERTENSIONAHA.118.12259 · Jennings A, Berendsen AM, de Groot LCPGM et al. · Hypertension 2019;73(5):1017–1026 · PMID 30636547 · RCT (NU-AGE trial) · n=1,294 randomised (1,142 completed; BP analysis n=1,128: 567 control + 561 intervention) adults age 65–79; 12-month Mediterranean-style diet intervention; SBP reduced −5.5 mm Hg (95% CI −10.7 to −0.4; P=0.03; males −9.2 mm Hg P=0.02; females −3.1 mm Hg P=0.37 ns); augmentation index −12.4 (95% CI −24.4 to −0.5; P=0.04) assessed in UK subset only (n=225); no significant change in pulse wave velocity; model: human older adults (5 European centres) ↩
doi:10.1056/NEJMoa2412006 · Bi Y, Li M, Liu Y et al.; BPROAD Research Group · N Engl J Med 2025;392(12):1155–1167 · PMID 39555827 · RCT · n=12,821 Chinese adults with type-2 diabetes; intensive (SBP <120) vs standard (<140); median follow-up ~4.2 yr; primary composite CV outcome HR 0.79 (95% CI 0.69–0.90; P<0.001); reconciles the earlier ACCORD-BP null toward the SPRINT-direction benefit in diabetes · model: human RCT (T2D) · gap/no-fulltext-access (verified against PubMed abstract/metadata; full text not re-read) ↩

🧬 Aging Wiki

Explorer

hypertension